Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
1.860
-0.050 (-2.62%)
At close: Jun 13, 2025, 4:00 PM
1.900
+0.040 (2.15%)
After-hours: Jun 13, 2025, 7:58 PM EDT
Nkarta Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
157
Market Cap
131.98M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NKTX News
- 8 days ago - Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus - GlobeNewsWire
- 4 weeks ago - Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Benzinga
- 4 weeks ago - Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 2 months ago - Nkarta to Participate in an April Investor Conference - GlobeNewsWire
- 2 months ago - Nkarta: Grinding Lower, Trying To Find Support - Seeking Alpha
- 2 months ago - Nkarta: Betting On The Turnaround - Seeking Alpha
- 2 months ago - Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
- 2 months ago - Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewsWire